Evaluating eye movement patterns in ADHD and autism
Exploring Eye Vergence Markers in Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
This study is testing how eye movement patterns can help us understand attention in children and adults with ADHD and autism.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | Child And Adult Neurodevelopment Assessment Ltd Academic / other |
| Locations | 3 sites (Barcelona, Catalonia and 2 other locations) |
| Trial ID | NCT06885060 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the role of eye vergence, a measure of eye movement, in understanding visuo-spatial attention in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Participants aged 4-17 years and adults will undergo computer-based eye-tracking tasks to explore the relationship between eye vergence and these neurodevelopmental conditions. The study will compare neuropsychological and behavioral data from clinical assessments with eye-tracking data to identify potential subgroups with specific attentional differences. The findings may contribute to early detection and targeted treatment strategies for attention deficits.
Who should consider this trial
Good fit: Ideal candidates include children and adults aged 4-17 years who are undergoing assessment for ADHD or ASD, as well as control subjects without these diagnoses.
Not a fit: Patients with non-corrected vision issues or other oculomotor deficiencies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance early detection and intervention strategies for ADHD and ASD, leading to improved patient outcomes.
How similar studies have performed: While the approach of using eye vergence as a diagnostic marker is relatively novel, similar studies have shown promise in linking eye-tracking measures to attentional control in neurodevelopmental conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical Groups: Patients currently undergoing or who have previously undergone an assessment for either ADHD and/or Autism at either the CAN centre or Dr Kilbey's private practice in Beckenham. * Control Group: Subjects without a diagnosis of either ADHD nor Autism, who show no traits of these conditions. * People of any gender/sex who are aged older than 6 years old. Exclusion Criteria: * Those with non-corrected vision - e.g. near-sightedness, far-sightedness, strabismus or nystagmus * Individuals with any other oculomotor deficiency, blindness or vision loss.
Where this trial is running
Barcelona, Catalonia and 2 other locations
- Braingaze SL — Barcelona, Catalonia, Spain (Recruiting)
- The Dr Kilbey Practice — Beckenham, London, United Kingdom (Recruiting)
- Child and Adult Neurodevelopment Assessment Ltd — New Malden, London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Elizabeth A Kilbey, BSc MSc MA DClinPsy CPsychol
- Email: elizabeth@drkilbey.com
- Phone: +44 7941 020746
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.